Neuronetics ranked #8 Holder of Pervasive Neurotech Intellectual Property*

.

Neu­ro­net­ics received FDA clear­ance for Neu­roStar TMS Ther­a­py in 2008. Neu­roStar uses tran­scra­nial mag­net­ic stim­u­la­tion as a form of neu­ro­mod­u­la­tion to treat depres­sion in patients who have not respond­ed ade­quate­ly to oth­er depres­sion treat­ments. The coil design was orig­i­nal­ly licensed from Emory Uni­ver­si­ty IP.

• Loca­tion: Malvern, PA
• Num­ber of employ­ees: 100–999
• Per­va­sive neu­rotech US patent grants: 21
• Per­va­sive neu­rotech US pend­ing appli­ca­tions: 9

*Neu­ro­net­ics ranked #8 in Sharp­Brains’ Per­va­sive Neu­rotech IP Strength Index, thanks to patents such as:

• US6926660: Facil­i­tat­ing treat­ment via mag­net­ic stimulation
• US7651459: Method and appa­ra­tus for coil posi­tion­ing for TMS studies
• US7104947: Deter­min­ing stim­u­la­tion lev­els for tran­scra­nial mag­net­ic stimulation
• US8118722: Reduc­ing dis­com­fort caused by elec­tri­cal stimulation

To learn more about Sharp­Brains’ take on the orga­ni­za­tion’s #Per­va­siveNeu­rotech IP port­fo­lio, and over­all data and trends, click on Per­va­sive Neu­rotech­nol­o­gy: A Ground­break­ing Analy­sis of 10,000+ Patent Fil­ings Trans­form­ing Med­i­cine, Health, Enter­tain­ment, and Busi­ness.